These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38324848)

  • 41. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis.
    Lev S
    Biochem Soc Trans; 2020 Apr; 48(2):657-665. PubMed ID: 32311020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
    Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
    Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
    Dees S; Pontiggia L; Jasmin JF; Mercier I
    Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
    Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
    BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progress in the Understanding of Estrogen Receptor Alpha Signaling in Triple-Negative Breast Cancer: Reactivation of Silenced ER-α and Signaling through ER-α36.
    Al-Kabariti AY; Abbas MA
    Mol Cancer Res; 2023 Nov; 21(11):1123-1138. PubMed ID: 37462782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
    Bilir B; Kucuk O; Moreno CS
    J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
    Jiang F; Li Y; Si L; Zhang Z; Li Z
    Cell Biol Toxicol; 2019 Aug; 35(4):361-371. PubMed ID: 30612216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
    Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
    BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer.
    Marini W; Wilson BE; Reedijk M
    DNA Cell Biol; 2023 Feb; 42(2):73-81. PubMed ID: 36579947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
    Zhang S; Chung WC; Miele L; Xu K
    Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent advances in targeted strategies for triple-negative breast cancer.
    Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
    Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
    Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.